Objective
to study the effect of loading doses of atorvastatin (2Ã80 mg) versus placebo on clinical outcomes prior to planned PCI for patients with ACS. All patients received 30 mg atorvastatin after 24 hours
Study
double-blind multicentre randomised trial
Population
patients with ACS and planned invasive management: 65% PCI, 8% CABG, 27% medical treatment
Endpoints
composite of all-cause death, MI, stroke and unplanned revascularisation through 30 days
Conclusion
Atorvastatin prior to planned PCI for patients with ACS did not reduce major adverse events at 30 days
Berwanger et al. JAMA. 2018;3:1113-18